Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
8-K
Departure of Directors or Certain Officers
11 Apr 24
8-K
Regulation FD Disclosure
9 Apr 24
S-8
Registration of securities for employees
29 Feb 24
S-3ASR
Automatic shelf registration
29 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
27 Feb 24
8-K
Amendments to Articles of Incorporation or Bylaws
15 Feb 24
8-K
Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments
25 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
10-Q
2023 Q3
Quarterly report
6 Nov 23
8-K
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
6 Nov 23
8-K
Departure of Directors or Certain Officers
6 Oct 23
8-K
Regulation FD Disclosure
13 Sep 23
8-K
Regulation FD Disclosure
9 Aug 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
8-K
Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates
9 Aug 23
8-K
Amendments to Articles of Incorporation or Bylaws
16 Jun 23
8-K
Other Events
15 Jun 23
424B5
Prospectus supplement for primary offering
15 Jun 23
FWP
Free writing prospectus
15 Jun 23
8-K
Other Events
15 Jun 23
8-K
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
6 Jun 23
8-K
Regulation FD Disclosure
5 Jun 23
8-K
Regulation FD Disclosure
26 May 23
DEFA14A
Additional proxy soliciting materials
10 May 23
10-Q
2023 Q1
Quarterly report
10 May 23
8-K
Zentalis Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates
10 May 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
8-K
Regulation FD Disclosure
26 Apr 23
PRE 14A
Preliminary proxy
18 Apr 23
8-K
Zentalis announces preclinical data supporting Cyclin E1 as a predictive marker for azenosertib treatment at AACR Annual Meeting 2023
17 Apr 23
8-K
Regulation FD Disclosure
10 Mar 23
8-K
Entry into a Material Definitive Agreement
9 Mar 23
10-K
2022 FY
Annual report
1 Mar 23
8-K
Zentalis Pharmaceuticals Reports Full Year 2022 Financial Results and Operational Updates
1 Mar 23
Latest ownership filings
3
Vincent Vultaggio
11 Apr 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
Avidity Partners Management LP
13 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
144
Notice of proposed sale of securities
12 Feb 24
144
Notice of proposed sale of securities
12 Feb 24
144
Notice of proposed sale of securities
12 Feb 24
4
Melissa B, Epperly
12 Feb 24
4
Cam Gallagher
12 Feb 24
SC 13G/A
Capital International Investors
9 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
9 Feb 24
4
DIANA HAUSMAN
5 Feb 24
4
Mark Lackner
5 Feb 24
4
Andrea Paul
5 Feb 24
4
Cam Gallagher
5 Feb 24
4
Melissa B, Epperly
5 Feb 24
4
Kimberly Blackwell
5 Feb 24
144
Notice of proposed sale of securities
2 Feb 24
144
Notice of proposed sale of securities
2 Feb 24
144
Notice of proposed sale of securities
2 Feb 24
144
Notice of proposed sale of securities
2 Feb 24
144
Notice of proposed sale of securities
2 Feb 24
144
Notice of proposed sale of securities
2 Feb 24
SC 13G/A
BlackRock Inc.
29 Jan 24
SC 13G/A
STATE STREET CORP
25 Jan 24
4
Mark Lackner
3 Jan 24
3
Mark Lackner
3 Jan 24
4
Kevin D. Bunker
21 Dec 23
SC 13G/A
EVENTIDE ASSET MANAGEMENT, LLC
11 Dec 23
SC 13G
CITADEL ADVISORS LLC
17 Nov 23
4
David Michael Johnson
13 Nov 23
4
Kimberly Blackwell
13 Nov 23
SC 13G
EVENTIDE ASSET MANAGEMENT, LLC
10 Oct 23
4
Carrie Brownstein
6 Oct 23
4
Kevin D. Bunker
6 Oct 23
4
Melissa B, Epperly
6 Oct 23
144
Notice of proposed sale of securities
4 Oct 23
144
Notice of proposed sale of securities
4 Oct 23
144
Notice of proposed sale of securities
4 Oct 23